Table 4.
Multivariate logistic regression analyses showing adverse effects associated to the vaccine brand received by the physical therapists who participated in the study.
| Adverse effects | AZ (n = 406) | PB (n = 141) | OR (95% CI) | p | Mo (n = 34) | OR (95% CI) | p |
|---|---|---|---|---|---|---|---|
| Pain at the place where the vaccine was administered | |||||||
| Yes | 330 (81.3) | 112 (79.4) | 1.61 (0.77–3.36) | 0.203 | 29 (85.3) | 0.93 (0.30–2.90) | 0.894 |
| Fever | |||||||
| Yes | 231 (56.9) | 44 (31.2) | 0.67 (0.40–1.13) | 0.132 | 15 (44.1) | 1.43 (0.60–3.40) | 0.421 |
| Headache | |||||||
| Yes | 219 (53.9) | 42 (29.8) | 0.49 (0.31–0.77) | 0.002* | 13 (38.2) | 0.69 (0.32–1.50) | 0.351 |
| Vomiting | |||||||
| Yes | 28 (6.9) | 2 (1.4) | 0.48 (0.11–2.13) | 0.332 | 1 (2.9) | 1.22 (0.14–10.5) | 0.858 |
| Tiredness | |||||||
| Yes | 264 (65.0) | 82 (58.2) | 1.48 (0.89–2.44) | 0.129 | 18 (52.9) | 0.92 (0.42–2.05) | 0.844 |
| Shivering | |||||||
| Yes | 208 (51.2) | 29 (20.6) | 0.34 (0.20–0.58) | <0.001* | 8 (23.5) | 0.32 (0.12–0.82) | 0.017* |
| Generalized muscle pain | |||||||
| Yes | 212 (52.2) | 50 (35.5) | 0.90 (0.54–1.49) | 0.678 | 6 (17.6) | 0.23 (0.08–0.62) | 0.004* |
| Inflammation of the ganglia | |||||||
| Yes | 36 (8.9) | 6 (4.3) | 0.56 (0.22–1.44) | 0.229 | 5 (14.7) | 0.12 (0.01–1.22) | 0.353 |
Data shown as n (percent within the vaccine brand). OR = calculated for each answer as compared to all the others; p = calculated for the Chi-square test group. The negative response to the presence of the adverse effect was taken as the reference value for the multivariate logistic regression analysis. AZ, AstraZeneca-Oxford; PB, Pfizer-BioNTech. Mo, Moderna.
*
p <0.05 Chi-square calculated as contingency table.